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Since its introduction in the late 1970s, one ofthe major drawbacks of percutaneous coro-
nary intervention (PCI) is restenosis [1]. The intro-
duction of intravascular stents was seen as a
solution to this problem; however, rates of
restenosis remained significantly high, giving rise
to a new dilemma—in-stent restenosis (ISR).
The introduction of drug-eluting stents (DESs)
was seen as a solution to this problem, and the
various technologies and materials used in their
manufacturing have succeeded to considerably
reduce the incidence of ISR. However, this early
enthusiasm led to increased use of DESs in a
diverse range of complex coronary lesions, leading
to a resurge in the rates of ISR [2,3]. Furthermore,
problems arising from the polymer or the drug-
release kinetics, in the early generations, have
hampered their antirestenosis efficacy [4].
DES-associated restenosis remains a problem-
atic issue despite the major innovations in the
stent design and components. According to the
most recent guidelines [5], DESs or drug-coated
balloons are recommended for the treatment of
DES-associated restenosis.
Nevertheless, data about the treatment of DES-
associated restenosis remain sparse and conflict-
ing. Some questions are still to be answered like
whether the same or different type of DES should
be used in cases of restenosis and what is the best
treatment strategy for DES rerestenosis? Does bal-
loon angioplasty (BA) play a role in such cases?
In an attempt to tackle this issue, we present an
observational follow-up study comparing DESs
with plain BA in the treatment of two groups of
patients; those with first-time DES-ISR and the
other was a group of patients with rerestenosis
of DES-treated DES-ISR.Materials and methods
Study design
This represents a single-center retrospective
observational study according to the institutional
protocols adopted at Kokura Memorial Hospital,
Kitakyushu, Japan. The data from consecutive
patients with DES-ISR were prospectively col-
lected and retrospectively analyzed in the depart-
mental electronic patient information system. The
study was performed according to the provisions
of the Declaration of Helsinki. The study protocol
was approved by the Institutional Review BoardPlease cite this article in press as: Abdelmegid M.-A.K.F. et al., Drug-el
restenosis: An observational follow-up study of first-time versus repeate
jsha.2016.10.001and Ethics Committee. Informed consent was
obtained from all patients.
Study population
Over a 3-year period, 123 consecutive patients
with 130 lesions undergoing TLR for DES resteno-
sis were included in the study. Among those, 84
patients (90 lesions) had first-time DES-ISR, while
39 patients (40 lesions) had repeated restenosis of
DES used to treat previous DES-ISR, i.e.,
rerestenosis subtending two layers of DESs
(Fig. 1). Follow-up coronary angiography was per-
formed in 108 patients (87.7%) at 1 year, according
to the institutional protocols. Clinical follow-up
data in the form of subsequent re-TLR was sched-
uled up to 2 years later.
PCI and procedural management
A bolus of 100 IU/kg of heparin was adminis-
tered after insertion of the sheath and titrated to
maintain an activated clotting time >250 seconds
throughout the procedure. PCI was performed
either with BA or with restenting by a different
DES according to the strategy adopted by Kokura
Hospital at that time. The selection of the device to
treat ISR was left to the operator’s discretion. All
patients received aspirin 100 mg indefinitely,
clopidgrel 75 mg/d for at least 12 months, and
other cardiac medications according to the clinical
condition.
End-points and definitions
Both angiographic follow-up scheduled at 1 year
and clinical follow-up for re-TLR at 2 years were
end-points for the study. TLR was defined as
first-time revascularization involving the target
DES-ISR lesions or within 5 mm from the stent
edges. Re-TLR refers to a second-time revascular-
ization for DES re-restenosis (i.e., restenosis sub-
tending 2 layers of DESs). Angiographic patterns
of restenosis, previously reported by Mehran
et al. [6], were used to classify in-stent restenosis
into four broad types: (1) focal ISR610 mm length;
(2) diffuse ISR >10 mm within the stent borders;
(3) proliferative ISR >10 mm beyond the stentuting stents or balloon angioplasty for drug-eluting stent-associated
d restenosis, J Saudi Heart Assoc (2016), http://dx.doi.org/10.1016/j.
Table 1. Baseline patients’ clinical characteristics.










Age (y) 70.9 ± 9.8 68.1 ± 5.8 NS 69.7 ± 9.5 74.7 ± 6.3 NS NS
Male 48 (77.4) 18 (81.8) NS 27 (90) 8 (88.9) NS NS
Hypertension 57 (91.9) 20 (90.9) NS 29 (96.7) 8 (88.9) NS NS
Dyslipidemia 42 (67.7) 16 (72.7) NS 22 (73.3) 7 (77.8) NS NS
Diabetes mellitus 40 (64.5) 13 (59.1) NS 18 (60) 6 (66.7) NS NS
DM on insulin 10 (16.1) 3 (13.6) NS 5 (16.7) 0 (0) NS NS
Current smoking 13 (21) 2 (9.1) NS 7 (23.3) 3 (33.3) NS NS
Prior MI 29 (46.8) 10 (45.5) NS 21 (70) 3 (33.3) NS NS
Prior CABG 4 (6.5) 1 (4.5) NS 4 (13.3) 2 (22.2) NS NS
Prior HF 9 (14.5) 5 (22.7) NS 6 (20) 1 (11.1) NS NS
PVD 17 (27.4) 5 (22.7) NS 8 (26.7) 4 (44.4) NS NS
eGFR 6 60 22 (35.5) 8 (36.4) NS 16 (53.3) 2 (22.2) NS NS
EF (%) 55.9 ± 12.4 57.9 ± 9.9 NS 52.5 ± 11.7 52.9 ± 14.1 NS NS
Data are presented as n (%) or mean ± standard deviation.
BA = balloon angioplasty; CABG = coronary artery bypass graft; DES = drug-eluting stents; DM = diabetes mellitus; EF = ejection fraction;
eGFR = estimated glomerular filtration rate; HF = heart failure; ISR = in-stent restenosis; MI = myocardial infarction; PVD = Peripheral vascular











Figure 1. Patient and lesion flow chart. DES = drug-eluting stents; ISR = in-stent restenosis; TLR = target lesion revascularization.
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DES VS. BA FOR DES RESTENOSIS AND RE-RESTENOSISborders; and (4) totally occluded ISR with Throm-
bolysis in Myocardial Infarction flow Grade 0.
Quantitative coronary angiography
Quantitative coronary angiography was per-
formed pre- and postintervention, as well as
1 year after the procedure (latter was available
for only 87.7% of patients). Quantitative angiogra-
phy was performed using a computer-assisted,
dedicated software package (CMS-MEDIS Medi-
cal Imaging System, Leiden, The Netherlands).Please cite this article in press as: Abdelmegid M.-A.K.F. et al., Drug-el
restenosis: An observational follow-up study of first-time versus repeate
jsha.2016.10.001Standard qualitative and quantitative definitions
and measurements were used [7]. Reference ves-
sel diameter, minimal lumen diameter, diameter
of stenosis, and lesion length were measured
using a single matched ‘‘worst’’ view. Acute
lumen gain was defined as the immediate gain
in the lumen size of the target lesion postinterven-
tion. Late luminal loss was defined as the differ-
ence between the minimal lumen diameter of
the target lesion immediately after the procedure
and at 1 year after PCI. Net lumen gain was theuting stents or balloon angioplasty for drug-eluting stent-associated
d restenosis, J Saudi Heart Assoc (2016), http://dx.doi.org/10.1016/j.
Table 2. Baseline lesion characteristics.










ACC/AHA lesion type NS NS NS
A 32 (48.5) 6 (25) 5 (16.7) 2 (20)
B1 15 (22.7) 7 (29.2) 11 (36.7) 5 (50)
B2 11 (16.7) 6 (25) 7 (23.3) 2 (20)
C 8 (12.1) 5 (20.8) 7 (23.3) 1 (10)
ISR pattern NS NS NS
Focal proximal edge 12 (18.2) 8 (33.3) 5 (16.6) 0 (0)
Focal stent body 32 (48.4) 7 (29.2) 11 (36.7) 4 (40)
Focal distal edge 5 (7.6) 1 (4.2) 2 (6.7) 0 (0)
Multifocal 5 (7.6) 2 (8.3) 6 (20) 4 (40)
Diffuse 7 (10.6) 1 (4.2) 3 (10) 1 (10)
Occlusive 5 (7.6) 5 (20.8) 3 (10) 1 (10)
CTO 4 (6.1) 3 (12.5) NS 2 (6.7) 1 (10) NS NS
Ostial 3 (4.5) 1 (4.2) NS 2 (6.7) 0 (0) NS NS
Bifurcation 4 (6.1) 6 (25) 0.02 3 (10) 1 (10) NS NS
Data are presented as n (%).
ACC/AHA = American College of Cardiology/American Heart Association; BA = balloon angioplasty; CTO = chronic total occlusion; DES = drug-








Table 3. Procedural characteristics.










Approach NS NS 0.014
Femoral 13 (19.7) 8 (33.3) 12 (40) 4 (40)
Brachial 32 (48.5) 11 (45.8) 16 (53.3) 5 (50)
Radial 21 (31.8) 5 (20.9) 2 (6.7) 1 (10)
Target vessel NS NS NS
LM 2 (3) 2 (8.3) 2 (6.7) 1 (10)
LAD 22 (33.3) 12 (50) 10 (33.3) 1 (10)
LCX 15 (22.7) 2 (8.3) 2 (6.7) 4 (40)
RI 1 (1.5) 0 (0) 0 (0) 0 (0)
RCA 26 (39.5) 7 (29.2) 15 (50) 4 (40)
Graft 0 (0) 1 (4.2) 1 (3.3) 0 (0)
IVUS guided 3 (4.5) 9 (37.5) 0.0002 3 (10) 1 (10) NS NS
Balloon type NS NS NS
Semi complaint 19 (28.8) 11 (45.8) 9 (30) 5 (50)
Non complaint 42 (63.6) 12 (50) 20 (66.7) 3 (30)
Other 5 (7.6) 1 (4.2) 1 (3.3) 2 (20)
Balloon diameter 2.6 ± 0.5 2.5 ± 0.6 NS 2.7 ± 0.5 2.6 ± 0.6 NS NS
Inflation pressure 17.0 ± 4.8 14.4 ± 3.4 NS 18.3 ± 4.2 14.4 ± 3.6 0.01 NS
Stent type NS
Cypher – 8 (33.4) – 4 (40)
Taxus – 15 (62.4) – 5 (50)
Cypher & taxus – 1 (4.2) – 1 (10)
Total stent length – 18.7 ± 8.2 – 21.0 ± 17.0 NS
Stent diameter – 2.8 ± 0.3 – 2.8 ± 0.4 NS
Inflation pressure – 16.2 ± 3.4 – 16.7 ± 2.7 NS
Data are presented as n (%) or mean ± standard deviation.
BA = balloon angioplasty; DES = drug-eluting stents; ISR = in-stent restenosis; IVUS = intravascular ultrasound; LAD = left anterior descending
artery; LM = left main; LCX = left circumflex artery; NS = nonsignificant; RCA = right coronary artery; RI = ramus intermedius.
4 ABDELMEGID ET AL
DES VS. BA FOR DES RESTENOSIS AND RE-RESTENOSIS
J Saudi Heart Assoc
2016;xxx:xxx–xxxdifference between acute lumen gain and late
lumen loss. Binary restenosis was defined as
P50% diameter of stenosis at follow-up angiographyPlease cite this article in press as: Abdelmegid M.-A.K.F. et al., Drug-el
restenosis: An observational follow-up study of first-time versus repeate
jsha.2016.10.001of a treated lesion. Similarly, rerestenosis was defined
as more than 50% diameter of stenosis by
quantitative coronary angiography on follow-up.uting stents or balloon angioplasty for drug-eluting stent-associated
d restenosis, J Saudi Heart Assoc (2016), http://dx.doi.org/10.1016/j.
Table 4. Quantitative coronary angiography: preintervention, postintervention, and at 1-year follow-up.
First-time DES-ISR Rerestenosis of DES-treated ISR p (overall)
BA (n = 66) Re-DES (n = 24) p BA (n = 30) Re-DES (n = 10) p
Pre-intervention
RVD (mm) 2.5 ± 0.4 2.5 ± 0.4 NS 2.6 ± 0.5 2.5 ± 0.3 NS NS
MLD (mm) 0.5 ± 0.3 0.5 ± 0.4 NS 0.5 ± 0.3 0.5 ± 0.3 NS NS
Lesion Length (mm) 6.9 ± 3.2 9.6 ± 5.3 0.005 10.1 ± 9.8 10.4 ± 6.3 NS 0.04
DS (%) 79.6 ± 9.8 82.1 ± 13.6 NS 79.5 ± 11.0 80.5 ± 12.1 NS NS
Postintervention
RVD (mm) 2.6 ± 0.4 2.8 ± 0.5 NS 2.6 ± 0.5 2.8 ± 0.4 NS NS
MLD (mm) 2.1 ± 0.4 2.4 ± 0.5 0.005 2.1 ± 0.3 2.4 ± 0.2 0.001 NS
ALG (mm) 1.5 ± 0.4 1.9 ± 0.3 <0.0001 1.5 ± 0.3 1.9 ± 0.4 0.01 NS
DS (%) 21.1 ± 7.4 14.4 ± 5.7 <0.0001 20.75 ± 5.3 12.6 ± 6.9 0.005 NS
Follow-upa
RVD (mm) 2.4 ± 0.4 2.6 ± 0.5 NS 2.5 ± 0.4 2.5 ± 0.3 NS NS
MLD (mm) 1.0 ± 0.6 1.8 ± 0.9 <0.0001 0.7 ± 0.6 1.3 ± 0.8 0.02 0.01
DS (%) 57.6 ± 22.7 32.8 ± 30.3 0.002 72.3 ± 21.7 47.9 ± 29.8 0.02 0.003
LLL (mm) 1.0 ± 0.5 0.6 ± 0.8 0.02 1.4 ± 0.6 1.1 ± 0.8 NS 0.001
NLG (mm) 0.5 ± 0.6 1.2 ± 0.8 <0.0001 0.2 ± 0.6 0.2 ± 0.7 NS NS
Binary restenosis 28 (49.1) 5 (25) 0.05 20 (71.4) 4 (50) NS 0.018
The same site of ISR 23 (82.1) 1 (20) 0.01 17 (85) 4 (50) NS NS
Re-ISR pattern NS NS NS
Focal proximal edge 5 (17.9) 1 (20) 3 (15) 0%
Focal stent body 15 (53.5) 3 (60) 12 (60) 10 (100)
Focal distal edge 2 (7.1) 0 (0) 1 (5) 0 (0)
Multifocal 2 (7.1) 0 (0) 1 (5) 0 (0)
Diffuse 4 (14.4) 0 (0) 2 (10) 0 (0)
Occlusive 0 (0) 1 (20) 1 (5) 0 (0)
Data are presented as n (%) or mean ± standard deviation.
ALG = acute lumen gain; BA = balloon angioplasty; DES = drug-eluting stents; DS = diameter stenosis; ISR = in-stent restenosis;; LLL = late lumen
loss; MLD = minimal lumen diameter; NLG = net lumen gain; NS = nonsignificant; RVD = reference vessel diameter.











Figure 2. Kaplan–Meier survival curves showing the 2-year cumulative incidence of re-target lesion revascularization (TLR) among first-time
drug-eluting stents-in-stent restenosis (DES-ISR; left) and rerestenosis of DES-treated DES-ISR (right) patient groups. BA = Balloon angioplasty.
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Continuous variables were expressed as
mean ± standard deviation, and categorical vari-
ables as frequency (%). Continuous variables werePlease cite this article in press as: Abdelmegid M.-A.K.F. et al., Drug-el
restenosis: An observational follow-up study of first-time versus repeate
jsha.2016.10.001compared using unpaired Student t test or analy-
sis of variance. Categorical variables were com-
pared with Chi-square test (v2) or Fisher’s exact
tests. Two-year clinical outcomes were analyzeduting stents or balloon angioplasty for drug-eluting stent-associated
d restenosis, J Saudi Heart Assoc (2016), http://dx.doi.org/10.1016/j.
Table 5. Re-target lesion revascularization incidence at 1-year and 2-year follow-up.
First-time DES-ISR Rerestenosis of DES-treated ISR p (overall)
BA (n = 66) Re-DES (n = 24) p BA (n = 30) re-DES (n = 10) p
1 y 21 (33.3) 3 (12.5) 0.04 13 (43.3) 4 (40) NS NS
2 y 25 (37.8) 4 (16.6) 0.03 18 (60) 5 (50) NS 0.01
Data are presented as n (%).
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with log-rank test pooled over strata. All tests
were two-sided and a p value <0.05 was consid-
ered significant. All analyses were performed with
SPSS version 18 (SPSS, Inc., Chicago, IL, USA).Results
One-hundred and twenty-three patients, sub-
tending 130 lesions, were included in the study.
Among those, 84 patients (90 lesions) had first-
time DES-ISR, while 39 patients (40 lesions) had
rerestenosis of DES-treated DES-ISR (Fig. 1). From
the first group, 62 patients (66 lesions) were trea-
ted by BA, while 22 patients (24 lesions) had re-
DES implantation. In the second group, 30
patients (30 lesions) were treated by BA, while
nine patients (10 lesions) had re-DES implanta-
tion. Table 1 shows the baseline clinical character-
istics of the study population. There were no
statistically significant differences between both
subgroups (BA or re-DES). Of notice, the majority
of patients were men, more than 90% were hyper-
tensive, around 70% had dyslipidemia, and almost
60% were diabetic. Tables 2 and 3 represent the
angiographic and procedural results. There were
no significant differences between the patients’
subgroups (BA vs. re-DES) of each major group
(1st-time DES-ISR vs. DES rerestenosis). The
majority of lesions were Type A in the first group
(1st-time DES-ISR), while the second group (DES
rerestenosis) had a majority of Type B1 lesions.
The ISR was of focal pattern in most of the lesions.
Complex lesions like chronic total occlusions and
bifurcation lesions were more frequently treated
by re-DES than BA. Almost two-thirds of the
patients had the procedure performed through
upper extremity, either radial or brachial. The
most frequently targeted vessels were the left
anterior descending artery and right coronary
artery. Intravascular ultrasound-guided PCI was
performed more often in re-DES strategy than
BA. Noncompliant balloon was used more often
than semicompliant balloon, especially in those
undergoing BA. Table 4 shows the quantitative
angiographic results at: (1) baseline; (2) immedi-Please cite this article in press as: Abdelmegid M.-A.K.F. et al., Drug-el
restenosis: An observational follow-up study of first-time versus repeate
jsha.2016.10.001ately postintervention; and (3) at 1-year follow-
up. Compared with baseline, postintervention
minimal lumen diameter and acute lumen gain
were significantly larger; the diameter of stenosis
was less in the re-DES strategy compared with
BA in both groups (1st-time DES-ISR vs. DES
rerestenosis). At 1-year angiographic follow-up,
quantitative measurements showed that minimal
lumen diameter was still significantly larger and
the diameter of stenosis was significantly smaller
in patients treated with re-DES compared with
BA in both patient groups. However, for the late
lumen loss and net lumen gain, it was only signif-
icantly different in the first-time DES-ISR in favor
of patients undergoing re-DES, while there was no
significant difference between both treatment
strategies among patients with DES rerestenosis.
Binary restenosis rates were high in both groups.
Of notice, binary restenosis rates were signifi-
cantly higher in the DES rerestenosis group com-
pared with first-time DES-ISR group.
Nevertheless, within the treatment subgroups,
binary restenosis rates tended to be significantly
higher in patients undergoing BA compared with
re-DES only in first-time DES-ISR patients. The
majority of rerestenosis was of focal pattern, more
often within the stent body and less often at the
stent edges (Table 4). Moreover, binary restenosis
occurred at the same previous site more often in
BA treatment compared with re-DES treatment
subgroups, which was statistically significant
among the first-time DES-ISR patient group only.
According to the Kaplan–Meier survival curves
(Fig. 2), the cumulative incidence of re-TLR among
First-time DES-ISR patients was significantly
higher in BA-treated patients than those undergo-
ing re-DES. This was not the case with patients
having rerestenosis of DES-treated ISR (Fig. 2).
Table 5 shows the incidence of re-TLR at 1- and
2-year clinical follow-up. Late catch-up phe-
nomenon, which is the delayed occurrence of clin-
ical restenosis warranting secondary
revascularization, was observed in both groups
comparing 1- and 2-year follow-ups, with signifi-
cantly higher rates in the rerestenosis of DES-
treated ISR group at 2 years (overall p = 0.01).uting stents or balloon angioplasty for drug-eluting stent-associated
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In this study, we compared the angiographic
and clinical outcomes after BA versus re-DES
among two groups of patients. The first group
included those with first-time DES-ISR, while
the patients in the second group had previous
DES-treated ISR of DES who developed
rerestenosis. At 1-year angiographic and up to 2-
year clinical follow-up, it was obvious that the bin-
ary restenosis and re-TLR rates, respectively, were
still relatively high in both patient groups. Among
the first group (1st-time DES-ISR), a strategy of re-
DES implantation resulted in a lower incidence of
angiographic restenosis and re-TLR than BA.
However, re-DES had no significant advantage
over BA in terms of angiographic restenosis or
re-TLR among the second group (rerestenosis in
DES-treated ISR).
Despite the different treatment strategies tested,
mostly in small retrospective studies, the optimal
treatment for DES-ISR remains unsettled. The ini-
tial enthusiasm with the use of DES to treat DES-
ISR has declined after clinical reports revealing
that clinical recurrences after interventions for
DES-ISR were two-fold those seen after bare-
metal stent-ISR [8], probably related to the differ-
ent underlying pathophysiological mechanism
and the composition of the restenosis tissue
[9,10]. This warrants further investigations to
unravel this mystery.
Previous large-scale studies have shown that a
strategy of re-DES is superior to BA in case of
DES-ISR [11–13]. A recent meta-analysis has con-
cluded that the use of BA should be discouraged
in patients with DES restenosis, owing to the
observation that BA had the lowest efficacy with
respect to all angiographic end-points as com-
pared with drug-eluting balloons or repeated
DES implantation. However, there was no data
on whether this reflects hard clinical outcomes.
Although a small number of patients were tested,
this study sheds some light upon an uprising issue
that we are currently confronted with in real-world
practice, with the wide off-label use of DES.
In accordance to previous studies and reports
[14,15], this study showed that DES-ISR patterns
were mostly focal. This predominant restenosis
pattern extends to second time DES-ISR as shown
in this study.
Our results are in agreement with that of Kita-
hara et al. [16], which showed that the rates of bin-
ary restenosis and TLR were less after adopting a
re-DES strategy compared with BA, among
patients with sirolimus-eluting stent restenosis.
Their study, however, showed that the benefit ofPlease cite this article in press as: Abdelmegid M.-A.K.F. et al., Drug-el
restenosis: An observational follow-up study of first-time versus repeate
jsha.2016.10.001re-DES implantation was confined to focal pattern
of DES-ISR, and does not hold much benefit com-
pared with BA when the ISR pattern is nonfocal.
To our knowledge, no previous study has tackled
the issue of repeated restenosis of DES used to treat
previous DES-ISR. This study represents the first
angiographic and clinical follow-up study address-
ing the issue of rerestenosis of DES-treated DES-
ISR. We observed no difference between a re-DES
strategy and BA among this patient subset in terms
of 1-yearbinary restenosis rates or re-TLRat 2 years.
In a recent optical coherence tomography study [17],
addressing the mechanisms of lumen gain in rein-
terventions for DES-ISR, lumen gain equally
resulted from a reduction of intrastent lumen vol-
ume (tissue compression) and further DES expan-
sion. We assume that probably the effect of the
latter is more pronounced in cases of rerestenosis
of DES-treated ISR. This might explain why BA
exerted the same benefit as re-DES among patients
treated for restenosis of DES-treated ISR.
Another previous optical coherence tomography
study showed that the morphologic appearance of
the restenosis tissue influenced the outcome [18],
where BA was more effective for DES-ISR with
heterogeneous tissue appearance than that with
homogenous/layered tissue. This warrants exten-
sive intravascular imaging research to explore
the morphology of restenosis tissue in repeated
ISR lesions, and explain why BA might perform
as good as re-DES in this patient subset.
In the scope of the relatively low restenosis rates
after DES implantation, it is difficult to conduct
large-scale trials. Thus, evaluation of optimum
treatment of DES-ISR remains a challenge. Rer-
estenosis rates, although increasingly observed,
are still scarce and this adds to the difficulty in
exploring this issue and increases the challenge.
This study has some limitations. Data were ana-
lyzed in a retrospective and nonrandomized man-
ner. Additionally, the sample size was small and
not powered enough to detect clinical end-
points, especially among the second group of
patients. However, the angiographic follow-up
rate was relatively high, approaching 90%, which
was higher than that reported in previous studies
from Japanese [16] or non-Japanese hospitals
[15,19]. In the present study, the underlying mech-
anisms of DES restenosis or rerestenosis were not
explored. Stent underexpansion, geographic miss,
or DES polymer damage [20–22] are possible
causes and should have been thoroughly evalu-
ated. Further large-scale studies, sufficiently pow-
ered for angiographic and clinical end-points, are
warranted to make this issue clear.uting stents or balloon angioplasty for drug-eluting stent-associated
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The rates of rerestenosis and re-TLR after
treatment of DES-ISR are relatively high. While
a strategy of re-DES would be better than BA in
first-time DES-ISR, this could not be extrapolated
to rerestenosis cases where no clear benefit could
be justified. Until further light is shed upon such
an uprising issue, BA could offer a better choice
for rerestenosis cases instead of putting further
stents when more than two stent layers are
already present in the vessel. Studies addressing
this subgroup of patients and exploring other
treatment strategies like drug-eluting balloons
and cutting balloons are eagerly awaited.
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